|
| 37946611 | Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents. | Br J Haematol | 2024 |
| 38086946 | Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. | Leukemia | 2024 |
| 38007585 | TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. | Leukemia | 2024 |
| 37794806 | Stressing the stem cell in acute myeloid leukemia. | Haematologica | 2024 |
| 38054837 | Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. | Leuk Lymphoma | 2024 |
| 36281717 | Integrated clinical genotype-phenotype characteristics of early T-cell precursor acute lymphoblastic leukemia. | Cancer | 2023 |
| 37635400 | Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. | Am J Hematol | 2023 |
| 37665752 | Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. | Am J Hematol | 2023 |
| 37585491 | Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. | Clin Cancer Res | 2023 |
| 37515433 | Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. | Am J Hematol | 2023 |
| 37842232 | Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia. | Cancer Drug Resist | 2023 |
| 37735426 | Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. | Blood Cancer J | 2023 |
| 37690903 | Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37608562 | Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. | Br J Haematol | 2023 |
| 35405739 | Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. | Blood Adv | 2023 |
| 37192303 | Preclinical characterization of ISB 1342, a CD38 ÿ CD3 T-cell engager for relapsed/refractory multiple myeloma. | Blood | 2023 |
| 36951163 | Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). | Haematologica | 2023 |
| 37422688 | A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. | J Hematol Oncol | 2023 |
| 37185307 | Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. | Leukemia | 2023 |
| 37386016 | A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. | Blood Cancer J | 2023 |
| 37441846 | Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. | Blood | 2023 |
| 37308342 | Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37104058 | Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. | Blood Adv | 2023 |
| 37102976 | A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies. | Blood Cancer Discov | 2023 |
| 37334870 | Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. | Am J Hematol | 2023 |
| 37070468 | What value do cell cycle inhibitors have in the treatment of myelodysplastic syndrome? | Expert Opin Pharmacother | 2023 |
| 37196217 | Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in <i>ABL</i> Class Rearrangements. | JCO Precis Oncol | 2023 |
| 37462435 | <i>IDH2</i> mutations in acute myeloid leukemia. | Leuk Lymphoma | 2023 |
| 36884300 | Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. | Blood Adv | 2023 |
| 36787422 | Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia. | Mol Cancer Res | 2023 |
| 36877196 | Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. | Am J Hematol | 2023 |
| 36715486 | Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. | Cancer | 2023 |
| 36801700 | PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. | Leuk Res | 2023 |
| 36799929 | A global study for acute myeloid leukemia with RARG rearrangement. | Blood Adv | 2023 |
| 36865338 | Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. | Res Sq | 2023 |
| 36458426 | A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. | Cancer | 2023 |
| 36565294 | Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. | Am J Hematol | 2023 |
| 36892949 | Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. | Cancer | 2023 |
| 36657414 | Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. | Leuk Lymphoma | 2023 |
| 35973199 | Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. | Blood Adv | 2023 |
| 36226489 | Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. | Haematologica | 2023 |
| 36350312 | A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. | Clin Cancer Res | 2023 |
| 36322818 | Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. | Blood Adv | 2023 |
| 36287248 | A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. | Blood Adv | 2023 |
| 34716921 | Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. | Am J Hematol | 2022 |
| 35384048 | Prediction of survival with intensive chemotherapy in acute myeloid leukemia. | Am J Hematol | 2022 |
| 35738590 | Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. | In Vivo | 2022 |
| 35583199 | Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. | Am J Hematol | 2022 |
| 35442137 | A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. | Leuk Lymphoma | 2022 |
| 35704787 | Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. | J Clin Oncol | 2022 |